Can docetaxel therapy improve overall survival from primary therapy compared with androgen-deprivation therapy alone in Japanese patients with castration-resistant prostate cancer? A multi-institutional cooperative study.

Tomoyuki Shimabukuro,Shigeru Sakano,Kenji Matsuda,Yoriaki Kamiryo,Norio Yamamoto,Yoshitaka Kaneda,Takahito Nasu,Yoshikazu Baba,Akinobu Suga,Mitsutaka Yamamoto,Akihiko Aoki,Kimio Takai,Satoru Yoshihiro,M Konishi,Katsuhiko Imoto,Hideyasu Matsuyama

Can docetaxel therapy improve overall survival from primary therapy compared with androgen-deprivation therapy alone in Japanese patients with castration-resistant prostate cancer? A multi-institutional cooperative study.

2013

Tomoyuki Shimabukuro
Shigeru Sakano
Kenji Matsuda
Yoriaki Kamiryo
Norio Yamamoto
Yoshitaka Kaneda
Takahito Nasu
Yoshikazu Baba
Akinobu Suga
Mitsutaka Yamamoto
Akihiko Aoki
Kimio Takai
Satoru Yoshihiro
M Konishi
Katsuhiko Imoto
Hideyasu Matsuyama

Background To verify the actual clinical benefit of docetaxel (DOC) therapy and to explore the prognostic factors that may predict overall survival in Japanese patients with castration-resistant prostate cancer (CRPC).

Keywords:

Prostate cancer
Primary therapy
Oncology
Androgen deprivation therapy
Castration
Internal medicine
Medicine
Docetaxel
Toxicity
overall survival
Surgical oncology
castration resistant

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations